Qurient Co. Ltd Cash Flow Conversion Efficiency
Qurient Co. Ltd cash flow conversion efficiency. Based on the latest financial reports, Qurient Co. Ltd (115180) has a cash flow conversion efficiency ratio of -0.374x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-8.15 Billion ≈ $-5.52 Million USD) by net assets (₩21.80 Billion ≈ $14.78 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Qurient Co. Ltd (2014–2025)
Cash flow conversion efficiency of Qurient Co. Ltd from 2014 to 2025. This chart illustrates how Qurient Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Qurient Co. Ltd stock quote for real-time trading data and today's change.
Qurient Co. Ltd Cash Flow Conversion Ratio Explained
Qurient Co. Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Qurient Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Qurient Co. Ltd ranked by their cash flow conversion efficiency. Also see Qurient Co. Ltd market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
init innovation in traffic systems SE
F:IXX
|
0.023x |
|
Sichuan Kexin Mechanic Electric
SHE:300092
|
0.018x |
|
Jiangxi Synergy Pharmaceutical Co Ltd
SHE:300636
|
0.027x |
|
ZJBC Information Technology Co Ltd
SHE:000889
|
0.058x |
|
Lanner Electronics
TWO:6245
|
0.034x |
|
GHCL Limited
NSE:GHCL
|
0.091x |
|
First Copper Technology Co Ltd
TW:2009
|
-0.011x |
|
Editas Medicine Inc
NASDAQ:EDIT
|
-0.281x |
Annual Cash Flow Conversion Efficiency for Qurient Co. Ltd (2014–2025)
The table below shows the annual cash flow conversion efficiency of Qurient Co. Ltd from 2014 to 2025. Review Qurient Co. Ltd financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩39.19 Billion ≈ $26.56 Million |
₩-28.67 Billion ≈ $-19.43 Million |
-0.732x | -80.73% |
| 2024-12-31 | ₩57.60 Billion ≈ $39.03 Million |
₩-23.32 Billion ≈ $-15.80 Million |
-0.405x | +14.10% |
| 2023-12-31 | ₩46.62 Billion ≈ $31.59 Million |
₩-21.97 Billion ≈ $-14.89 Million |
-0.471x | +33.78% |
| 2022-12-31 | ₩35.14 Billion ≈ $23.81 Million |
₩-25.00 Billion ≈ $-16.94 Million |
-0.712x | -57.89% |
| 2021-12-31 | ₩54.08 Billion ≈ $36.65 Million |
₩-24.37 Billion ≈ $-16.52 Million |
-0.451x | -28.45% |
| 2020-12-31 | ₩56.57 Billion ≈ $38.33 Million |
₩-19.85 Billion ≈ $-13.45 Million |
-0.351x | +74.59% |
| 2019-12-31 | ₩17.38 Billion ≈ $11.78 Million |
₩-24.00 Billion ≈ $-16.26 Million |
-1.381x | -294.23% |
| 2018-12-31 | ₩39.41 Billion ≈ $26.70 Million |
₩-13.80 Billion ≈ $-9.36 Million |
-0.350x | +59.55% |
| 2017-12-31 | ₩14.53 Billion ≈ $9.85 Million |
₩-12.59 Billion ≈ $-8.53 Million |
-0.866x | -113.10% |
| 2016-12-31 | ₩24.35 Billion ≈ $16.50 Million |
₩-9.90 Billion ≈ $-6.71 Million |
-0.406x | +84.40% |
| 2015-12-31 | ₩2.89 Billion ≈ $1.96 Million |
₩-7.54 Billion ≈ $-5.11 Million |
-2.605x | -950.52% |
| 2014-12-31 | ₩-21.68 Billion ≈ $-14.69 Million |
₩-6.64 Billion ≈ $-4.50 Million |
0.306x | -- |
About Qurient Co. Ltd
Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company's pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as … Read more